Skip to main content

Advertisement

SpringerLink
Log in

Targeting integrin-linked kinase increases apoptosis and decreases invasion of myeloma cell lines and inhibits IL-6 and VEGF secretion from BMSCs

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

In this study, we investigated ILK expression in myeloma cell lines U266 and H929 kept in suspension and cocultured with BMSCs, and studied the pharmacologic inhibitors of ILK on the apoptosis, invasive potential of myeloma cell lines, and production of pro-angiogenic factors of bone marrow stromal cells. We found that ILK protein was expressed in U266 and H929 cells and kinase activity was elevated when cocultured with BMSCs. ILK inhibitor QLT0267 reduced ILK kinase activity and increased apoptosis both in myeloma cell lines kept in suspension and cocultured with BMSCs. ILK inhibition by ILK inhibitor decreased the in vitro invasive capability of myeloma cell lines. In addition, QLT0267 significantly decreased VEGF and IL-6 secretion in BMSCs in a dose-dependent fashion. The results indicated that inhibition of ILK may provide a potential target for myeloma therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

MM:

Multiple myeloma

BM:

Bone marrow

ILK:

Integrin-linked kinase

BMSCs:

Bone marrow stromal cells

DNR:

Daunorubicin

References

  1. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776–83.

    Article  PubMed  CAS  Google Scholar 

  2. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36.

    Article  PubMed  CAS  Google Scholar 

  3. Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2007;25:LBA8025. (Meeting Abstracts).

    Google Scholar 

  4. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383–95.

    Article  PubMed  CAS  Google Scholar 

  5. Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028:390–9.

    Article  PubMed  CAS  Google Scholar 

  6. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607–18.

    Article  PubMed  CAS  Google Scholar 

  7. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, et al. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther. 2005;4:1681–8.

    Article  PubMed  CAS  Google Scholar 

  8. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 2006;66:393–403.

    Article  PubMed  CAS  Google Scholar 

  9. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther. 2005;4:1146–56.

    Article  PubMed  CAS  Google Scholar 

  10. Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem. 1998;273:528–36.

    Article  PubMed  CAS  Google Scholar 

  11. Ito R, Oue N, Zhu X, Yoshida K, Nakayama H, et al. Expression of integrin-linked kinase is closely correlated with invasion and metastasis of gastric carcinoma. Virchows Arch. 2003;442:118–23.

    PubMed  CAS  Google Scholar 

  12. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993;53:4143–7.

    PubMed  CAS  Google Scholar 

  13. Wong RP, Ng P, Dedhar S, Li G. The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol Cancer Ther. 2007;6(6):1692–700.

    Article  PubMed  CAS  Google Scholar 

  14. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res. 2001;61:3071–6.

    PubMed  CAS  Google Scholar 

  15. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950–61.

    Article  PubMed  CAS  Google Scholar 

  16. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor in the pathogenesis of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519–27.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The research is granted by National Natural Science Foundation of China.

Author information

Authors and Affiliations

  1. Department of Hematology, Key Laboratory of Cancer Prevention and Therapy, Cancer Hospital of Tianjin, Tianjin Medical University, Tianjin, 300060, People’s Republic of China

    Xiaofang Wang

  2. Department of Neurology, Dalian Central Hospital, Dalian, 116001, People’s Republic of China

    Zhiqing Zhang

  3. Department of Hematology, The First Hospital, Jilin University, Xinmin Street, Changchun, 130031, People’s Republic of China

    Cheng Yao

Authors
  1. Xiaofang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiqing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cheng Yao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, X., Zhang, Z. & Yao, C. Targeting integrin-linked kinase increases apoptosis and decreases invasion of myeloma cell lines and inhibits IL-6 and VEGF secretion from BMSCs. Med Oncol 28, 1596–1600 (2011). https://doi.org/10.1007/s12032-010-9616-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9616-y

Keywords

Search

Navigation